There is extensive evidence that immune mechanisms are involved in the pathogenesis of multiple sclerosis (MS 
The potential effects of IVIg could be mediated by several mechanisms. 5 IVIg from large pools of normal donors may contain anti-idiotypic antibodies which can: 1) neutralise circulating autoantibodies against myelin proteins; 2) interact with V regions of autoantibodies, selectively stimulate autoreactive B cell clones that are capable of idiotypic interactions with V regions of IVIg, and thus restore the physiological pattern of spontaneous fluctuations of the concentration of autoantibodies in plasma; 3) bind to specific epitopes of the T-cell receptor of certain regulatory T-cells and thereby cause suppression of inducer T-cells and B-cells. 6 Furthermore, IVIg can downregulate cytokine production and/or neutralise inflammatory cytokines (IL-1, IL-2, IL-6, INF-y, and IL-2 receptor). Schuller and Govaerts" treated 31 moderately disabled MS patients (mean Kurtzke score 4) with IgG. All patients initially received intramuscular injections of gammaglobulin 5 g three times a week for at least one year. Later they used IVIg 5 g/week (equals 0 3 g/kg/month). The treatment was continued for a mean period of four years. Overall, one third improved, one third were stable and one third deteriorated.
IVIg was used for treatment of acute exacerbations by Soukop and Tschabitscher"2 in a study of 27 patients of whom 22 had a relapsing-remitting type and five had a primary progressive type of MS. IVIg was administered in small doses (50 mg/kg) during an acute exacerbation or progression for a period of two to three weeks. In 16 (62%) of the patients IVIg treatment resulted in improvement in neurological score, usually within 24 hours.
Recently, Achiron et all' treated 10 patients with relapsing-remitting MS with IVIg 0 4 g/kg/day for five days followed by 0-4 g/kg, once every two months, for 12 months. Ten untreated patients matched for age and disease characteristics served as controls. A significant decrease in attack frequency was seen in IVIg treated patients from 3-7 (1.2) in the year before treatment to 1-0 (0 7) per year during IVIg treatment, whilst it remained unaltered in the controls. No significant difference was found in change in the Kurtzke EDSS score between the two groups. units in a two year trial.'6 Thus it appears that the evaluation of disease activity using MRI is a far more sensitive measurement of treatment response than changes in neurological function or disability. For example, a placebo-controlled trial with parallel groups with 2p = 0 05 and a statistical power of 80% would need to include 80 patients if a 50% reduction in MRI activity is used as an efficacy parameter, while the number of patients required would be 200 if an increase in EDSS . 1 is used as an efficacy parameter.
Methodology of clinical trials of IVIg in MS
For the study-design, crossover studies are more powerful than parallel group designs, the latter usually needing three to four times as many patients to achieve the same statistical power. For example, a placebo-controlled trial using MRI every four weeks in one year and a 50% reduction of MRI activity as outcome measure (2p = 0 05 and power 80%) would require 25 patients in a crossover trial and 100 patients in a trial with parallel groups. Unfortunately, in immunomodulatory treatments for MS the duration of the effect is unknown and, thus, it is difficult to determine the required length of the wash-out period between the two treatment periods in a crossover trial.
In crossover trials with frequent monitoring of Gadolinium-enhancing lesions, MRI as outcome measure has advantages in pilot trials of new prospective drugs for treatment of MS, because the number of patients and the duration of treatment can be reduced.
Design of a placebo-controlled, doubleblind crossover study We have undertaken a randomised, placebocontrolled, crossover study of IVIg using serial MRI for evaluation of efficacy. Patients with relapsing-remitting course of MS with at least two clinical MS attacks within the previous 12 months or with progressive-relapsing disease with progression within the previous year are included. Half of the patients are treated with IVIg (Gammagard) 1I0 g/kg body weight daily for two consecutive days at intervals of four weeks over a period of six months. After this, the patients will have a three month wash-out period without treatment, followed by six months of placebo treatment with an identical regime. The other half of the patients are treated with placebo followed by IVIg. The primary efficacy parameter is the number of new contrast enhancing lesions shown in serial MRI with intervals of four weeks during the treatment and control period. Secondary efficacy parameters are the number of clinical attacks, and changes in neurological function, for example, Neurological Rating Scale (NRS) and Expanded Disability Status Scale (EDSS). MRI is performed using a wholebody MRscanner at 1i5 Tesla with intravenous injection of Gadolinium-DPTA (Gd-DPTA). MRIs are evaluated "blind" and the number and size of lesions showing enhancement after injection of Gd-DPTA are measured. Statistical analysis will be performed using the Mann-Whimey U-test of the crossover study with two periods. The analysis is made with 2p = 0 05, type 2 error 20%, and the smallest relevant difference (Miredif) = 0 5. With these preconditions, the required number of patients will be 22.
Conclusion
At present, evidence for the efficacy of IVIg in the treatment of MS is based on a limited number of small open trials of which some have shown encouraging results. Assessment of efficacy must await the results of placebocontrolled, double-blind studies. A crossover trial with MRI for monitoring the treatment effect is ongoing and may provide evidence of the control of disease activity with IVIg treatment. However, the ultimate goal for treatment is to improve the clinical condition and function of the patients. Crossover trials using MRI changes as efficacy parameter should therefore be followed by studies of parallel groups with large numbers of patients followed for long periods with repeated clinical observations of neurological function, for example, EDSS or NRS.
